Skip to content

CAPRICOR THERAPEUTICS, INC.: 10-Q filed 2011-11-14

What CAPRICOR THERAPEUTICS, INC. reported in its quarterly report filed 2011-11-14 (fiscal Q3 2011): 29 published measures, 94 facts as tagged in accession 0001144204-11-063380.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-14
Fiscal period
fiscal Q3 2011
Accession
0001144204-11-063380 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CAPRICOR THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-303,090,813USD
At 2010-12-313,665,953USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-302,372,996USD
At 2010-12-312,596,868USD
At 2009-12-312,982,150USD
At 2008-12-315,103,618USD
At 2007-12-3115,199,932USD
At 2006-12-31-2,576,515USD
At 2005-12-31-5,043USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-302,607,336USD
At 2010-12-313,378,155USD
At 2010-09-304,435,833USD
At 2009-12-313,175,718USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,144,073USD92
2011-01-01 to 2011-09-30-3,220,396USD273
2005-08-01 to 2011-09-30-43,150,590USD2252
2010-01-01 to 2010-12-31-6,031,491USD365
2010-07-01 to 2010-09-30-1,809,493USD92
2010-01-01 to 2010-09-30-5,235,834USD273
2009-01-01 to 2009-12-31-7,872,297USD365
2008-01-01 to 2008-12-31-13,131,596USD366
2007-01-01 to 2007-12-31-10,302,795USD365
2006-01-01 to 2006-12-31-2,581,972USD365
2005-08-01 to 2005-12-31-10,043USD153

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-3,080,632USD273
2005-08-01 to 2011-09-30-31,135,819USD2252
2010-01-01 to 2010-09-30-3,262,791USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2005-08-01 to 2011-09-30128,868USD2252

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-07-01 to 2011-09-30813,000USD92
2011-01-01 to 2011-09-301,159,000USD273
2005-08-01 to 2011-09-301,641,235USD2252

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-09-302,309,813USD273
2005-08-01 to 2011-09-3034,215,114USD2252
2010-01-01 to 2010-09-304,522,906USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2005-08-01 to 2011-09-30-471,959USD2252

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-09-30-43,150,590USD
At 2010-12-31-39,930,194USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-09-3010,886USD
At 2010-12-3116,765USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-09-30686,711USD273
2005-08-01 to 2011-09-3010,185,844USD2252
2010-01-01 to 2010-09-301,034,654USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,156,364USD92
2011-01-01 to 2011-09-30-3,234,209USD273
2005-08-01 to 2011-09-30-42,820,345USD2252
2010-07-01 to 2010-09-30-1,812,736USD92
2010-01-01 to 2010-09-30-5,250,567USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-303,027,989USD
At 2010-12-313,597,250USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2005-08-01 to 2011-09-301,273,734USD2252

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-30717,817USD
At 2010-12-311,069,085USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-09-30504,333USD
At 2010-12-31332,380USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,969,364USD92
2011-01-01 to 2011-09-304,393,209USD273
2005-08-01 to 2011-09-3044,461,580USD2252
2010-07-01 to 2010-09-301,812,736USD92
2010-01-01 to 2010-09-305,250,567USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,470,091USD92
2011-01-01 to 2011-09-302,795,354USD273
2005-08-01 to 2011-09-3028,654,293USD2252
2010-07-01 to 2010-09-301,148,641USD92
2010-01-01 to 2010-09-303,517,822USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-09-3039,707,764shares
At 2010-12-3134,629,794shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-09-3045,483,878USD
At 2010-12-3142,492,432USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-3051,938USD
At 2010-12-3151,938USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-09-30420,653USD
At 2010-12-31219,095USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30499,273USD92
2011-01-01 to 2011-09-301,597,855USD273
2005-08-01 to 2011-09-3015,807,287USD2252
2010-07-01 to 2010-09-30664,095USD92
2010-01-01 to 2010-09-301,732,745USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-01-01 to 2011-09-305,879USD273
2005-08-01 to 2011-09-30319,020USD2252
2010-01-01 to 2010-09-3010,709USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-07-01 to 2011-09-3010,411USD92
2011-01-01 to 2011-09-308,901USD273
2005-08-01 to 2011-09-30150,618USD2252
2010-07-01 to 2010-09-30-2,711USD92
2010-01-01 to 2010-09-30-2,793USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-07-01 to 2011-09-3012,291USD92
2011-01-01 to 2011-09-3013,813USD273
2005-08-01 to 2011-09-30-330,245USD2252
2010-07-01 to 2010-09-303,243USD92
2010-01-01 to 2010-09-3014,733USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2005-08-01 to 2011-09-305,000USD2252

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-30171,953USD273
2005-08-01 to 2011-09-30504,333USD2252
2010-01-01 to 2010-09-30440,925USD273

Inspect the source

Entity
CAPRICOR THERAPEUTICS, INC. / CIK 0001133869
Captured
2026-09-20T07:41:24.575Z
SEC response SHA-256
b9f947143784aa2a5b7cc0470638338f21bd5664475f1be49c554014f98dbf5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001133869.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))